A5009045622- Pulmonary Hypertension Research and Treatments
- Cardiac and Coronary Surgery Techniques
- Protein Tyrosine Phosphatases
- Sphingolipid Metabolism and Signaling
- MicroRNA in disease regulation
- Heart Rate Variability and Autonomic Control
- Pneumocystis jirovecii pneumonia detection and treatment
- Cardiac Imaging and Diagnostics
- Cardiovascular Syncope and Autonomic Disorders
- Blood Pressure and Hypertension Studies
- Circular RNAs in diseases
- Thyroid Cancer Diagnosis and Treatment
- High Altitude and Hypoxia
- Cardiovascular and Diving-Related Complications
- Potassium and Related Disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- RNA modifications and cancer
- Thyroid Disorders and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
Harvard University
2024
Queen Elizabeth Hospital Birmingham
2024
Boston Children's Hospital
2024
University of Notre Dame
2020-2023
Mike and Josie Harper Cancer Research Institute
2020-2023
Indiana University School of Medicine
2022
Indiana University
2022
Cancer Research Institute
2022
University of Colombo
2016
Epigenetic regulation of vascular remodeling in pulmonary hypertension (PH) is poorly understood. Transcription regulating, histone acetylation code alters chromatin accessibility to promote transcriptional activation. Our goal was identify upstream mechanisms that disrupt epigenetic equilibrium PH.
Pulmonary Hypertension (PH) is a terminal disease characterized by severe pulmonary vascular remodeling. Unfortunately, targeted therapy to prevent progression limited. Here, the cell populations that contribute molecular and morphological changes of PH in conjunction with current animal models for studying remodeling will be examined. The status quo epigenetic targeting treating different subtypes dissected, while parallel threads between hypertension pathogenic cancer provide insight into...
Abstract Background Light chain cardiac amyloidosis (AL-CA) results in restrictive cardiomyopathy associated with progressive heart failure and poor survival. Traditionally, outcomes following transplantation patients AL-CA have been worse than other cohorts consequently, many centres do not offer this population transplantation. Purpose Methods This was a retrospective observational study of 18 (age 52.7years +/- 8.3, male 66%) referred to our centre the UK for assessment from 2008 2023....